ArticleJournal of translational medicine2026
Nanopore-targeted sequencing improves the diagnosis and treatment of patients with infectious ascites.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAscites, a pathological accumulation of fluid in the peritoneal cavity, often accompanies advanced liver disease or malignancy and can lead to spontaneous bacterial peritonitis (SBP), a life-threatening infection. Rapid pathogen identification is critical for SBP management, yet conventional ascites culture is slow and yields a pathogen in only ~ 20% of cases, leading to frequent broad-spectrum antibiotic use without identification of the causative pathogen.
methodsWe evaluated a nanopore-targeted sequencing (NTS) assay for rapid, comprehensive pathogen detection in ascitic fluid. Ascites samples from 1,173 patients were analyzed by NTS; conventional culture was performed on 616 of these samples for comparison. NTS simultaneously amplifies and sequences bacterial 16S rRNA, fungal ITS, and Mycobacterium rpoB gene targets. Diagnostic yields and changes in infection markers with therapy were utilized to evaluate the clinical value of NTS in the management of ascites.
resultsHere we show that NTS outperforms culture, detecting pathogens in 81.0% of cases (499/616) versus 16.8% (104/616) by culture (p < 0.001). NTS identifies pathogens in 399 culture-negative cases and uncovers polymicrobial infections and difficult-to-culture organisms (anaerobes, fungi, Mycobacterium) that standard methods miss. In SBP patients (n = 56), NTS achieves an 82% pathogen detection rate versus 38% by culture. Patients managed with NTS-guided targeted antibiotics show faster declines in procalcitonin (PCT) than those on empirical therapy.
conclusionsNTS is a rapid, sensitive diagnostic approach for ascitic infections that significantly improves pathogen identification and enables earlier targeted therapy. Its implementation could improve clinical outcomes and antibiotic stewardship in patients with ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.